Targeting neurolysin in acute myeloid leukemia

Sara Mirali; Aaron D Schimmer

doi:10.1080/23723556.2020.1761243

Targeting neurolysin in acute myeloid leukemia

Mol Cell Oncol. 2020 May 23;7(4):1761243. doi: 10.1080/23723556.2020.1761243. eCollection 2020.

Authors

Sara Mirali^{1

2}, Aaron D Schimmer^{1

2}

Affiliations

¹ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Department of Medicine, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

Abstract

We recently identified the mitochondrial peptidase, neurolysin (NLN), as a top hit in an acute myeloid leukemia (AML) viability screen. Using chemical and genetic approaches, we demonstrated that loss of NLN disrupted respiratory chain supercomplex assembly and impaired oxidative metabolism in AML. Moreover, inhibition of NLN in vitro and in vivo reduced the growth of AML cells.

Keywords: Acute myeloid leukemia; LETM1; metabolism; neurolysin; respiratory chain supercomplexes.

Grants and funding

This work was supported by the Ontario Institute for Cancer Research; Canadian Institutes of Health Research (CA); Canadian Institutes of Health Research (CA); Princess Margaret Cancer Foundation.